- Home
- SLNO vs BEAM Comparison
SLNO vs BEAM Comparison
Compare SLNO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- BEAM
- Stock Information
- Founded
- SLNO 1999
- BEAM 2017
- Country
- SLNO United States
- BEAM United States
- Employees
- SLNO N/A
- BEAM N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLNO Health Care
- BEAM Health Care
- Exchange
- SLNO Nasdaq
- BEAM Nasdaq
- Market Cap
- SLNO 1.9B
- BEAM 1.9B
- IPO Year
- SLNO 2014
- BEAM 2020
- Fundamental
- Price
- SLNO $54.63
- BEAM $23.58
- Analyst Decision
- SLNO Strong Buy
- BEAM Buy
- Analyst Count
- SLNO 7
- BEAM 11
- Target Price
- SLNO $69.86
- BEAM $45.90
- AVG Volume (30 Days)
- SLNO 504.7K
- BEAM 1.3M
- Earning Date
- SLNO 11-06-2024
- BEAM 11-05-2024
- Dividend Yield
- SLNO N/A
- BEAM N/A
- EPS Growth
- SLNO N/A
- BEAM N/A
- EPS
- SLNO N/A
- BEAM N/A
- Revenue
- SLNO N/A
- BEAM $349,643,000.00
- Revenue This Year
- SLNO N/A
- BEAM N/A
- Revenue Next Year
- SLNO N/A
- BEAM $6.04
- P/E Ratio
- SLNO N/A
- BEAM N/A
- Revenue Growth
- SLNO N/A
- BEAM 328.73
- 52 Week Low
- SLNO $26.38
- BEAM $20.84
- 52 Week High
- SLNO $59.75
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- SLNO 51.30
- BEAM 45.28
- Support Level
- SLNO $50.69
- BEAM $23.67
- Resistance Level
- SLNO $59.75
- BEAM $25.87
- Average True Range (ATR)
- SLNO 2.47
- BEAM 2.23
- MACD
- SLNO -0.48
- BEAM -0.24
- Stochastic Oscillator
- SLNO 43.47
- BEAM 19.58
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.